Qureight Secures $20M for AI-Powered Clinical Trials
July 30, 2026, 3:35 pm
Qureight secured $20 million in Series B funding. Molten Ventures led the round, joined by existing investors. This capital fuels Qureight's AI-powered imaging platform. It targets lung and heart clinical trials. The technology accelerates drug development. Qureight's platform reduces imaging decision times dramatically. New funds establish an in-house 3D deep learning lab. This enables rapid expansion into new diseases. Focus areas include asthma, lung cancer, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity. Qureight aims for global leadership in precision medical imaging. The investment strengthens its end-to-end regulatory compliant platform. It solidifies Qureight's position in a growing $27.5 billion market. The company plans significant growth and innovation.
Qureight, a leader in AI-powered medical imaging, closed a significant $20 million Series B funding round. This substantial investment bolsters its mission. The company aims to revolutionize lung and heart clinical trials. Molten Ventures spearheaded the funding. Existing investors also participated, reaffirming confidence in Qureight's vision. These included Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension.
The new capital fuels Qureight's advanced AI imaging platform. It will accelerate drug discovery. The funding prioritizes building an in-house AI imaging laboratory. This lab will house Qureight’s 3D chest imaging Foundation Model. Such a model reduces data requirements. It also drastically cuts development time for new disease models. This strategic move propels Qureight into new therapeutic areas.
Qureight targets critical lung and heart diseases. These include asthma, lung cancer, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity. The company already holds a strong position in lung fibrosis. Expanding into these new markets addresses unmet needs. It solidifies Qureight's standing. The platform provides enterprise-grade imaging and precision endpoints for clinical trials.
The company's technology offers tangible benefits. It features two core products. "Workflow" slashes imaging decision times. Processes that once took weeks now conclude in 48 hours. "AI Lung" models airways and blood vessels. This product precisely shows drug effects on disease progression. Both applications run on a general-purpose foundation model of the chest. This foundational approach allows rapid deployment of disease-specific models. What once took a year now takes mere months.
Qureight’s platform goes beyond basic imaging. It offers comprehensive global imaging CRO services. These improve image handling in trials. They support rapid site onboarding. They also streamline patient inclusion decisions. Proprietary AI Lung image biomarkers are a key component. These quantify structural changes. They track disease progression with precision. The platform also provides data science products. Synthetic control arms enable comparisons to real trial arms. This reduces study costs and duration.
The global lung and heart clinical trials market shows immense potential. Projections indicate a value of $27.5 billion by 2030. This represents a robust compound annual growth rate (CAGR) of 6.9%. Qureight positions itself strategically within this expanding market. Its end-to-end integrated imaging platform addresses a critical demand. It accelerates clinical trials.
Co-founder Dr. Muhunthan Thillai's personal experience fueled Qureight's inception. As a chest physician, he encountered difficulties interpreting complex CT scans. This experience highlighted a market gap. Pharmaceutical companies needed better tools for clinical trials. Qureight emerged to fill this void in 2018. The company quickly assembled a top-tier team. It hired a CTO from Hewlett Packard. A CMO from CMR Surgical joined. A CSO specializing in machine learning from Imperial College London completed the leadership. This expertise bridged early engineering gaps.
Qureight currently collaborates with major biopharma partners. AstraZeneca and Bristol Myers Squibb are among them. Various biotech partners also utilize its services. These partnerships provide real-time insights. They deliver precision endpoints for accelerated clinical trials. The company's models enhance efficiency. They improve the design of trials.
The decision to partner with Molten Ventures was deliberate. Molten had initially passed on Qureight two years prior. This time, Qureight received multiple term sheets from lead investors. They could have raised even more capital. However, Qureight chose Molten. The relationship proved crucial. It kept the funding round anchored to a London fund. This decision prioritized strategic alignment over competing US offers. Molten Ventures boasts a strong healthtech portfolio. Their investments include Deciphex and CoachHub.
Qureight envisions significant expansion. The company plans to double its headcount to 100 by December. A second London office opens next month. New trials in asthma, lung cancer, and pulmonary hypertension will launch before year-end. This aggressive growth strategy underscores Qureight's ambition. It aims to become the default imaging layer for pharma trials.
The company distinguishes itself from competitors. Oxford's Brainomix is a European peer. Brainomix offers an FDA-cleared e-Lung platform. It focuses on diagnostic software for hospitals. Qureight's focus differs. It provides trial design and imaging contract research services. This distinction creates a clear market segment for Qureight. Its platform was recently selected by Boehringer Ingelheim for a Phase 3 trial.
This $20 million investment marks a pivotal moment. It validates Qureight's innovative approach. It reinforces its leadership in AI-driven medical imaging. The capital ensures Qureight continues to push boundaries. It drives the next generation of medical innovation. The future of clinical trials will rely on such advanced technologies. Qureight is at the forefront of this transformation. Its AI platform promises faster, more accurate drug development. This ultimately benefits patients globally.
Qureight, a leader in AI-powered medical imaging, closed a significant $20 million Series B funding round. This substantial investment bolsters its mission. The company aims to revolutionize lung and heart clinical trials. Molten Ventures spearheaded the funding. Existing investors also participated, reaffirming confidence in Qureight's vision. These included Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension.
The new capital fuels Qureight's advanced AI imaging platform. It will accelerate drug discovery. The funding prioritizes building an in-house AI imaging laboratory. This lab will house Qureight’s 3D chest imaging Foundation Model. Such a model reduces data requirements. It also drastically cuts development time for new disease models. This strategic move propels Qureight into new therapeutic areas.
Qureight targets critical lung and heart diseases. These include asthma, lung cancer, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity. The company already holds a strong position in lung fibrosis. Expanding into these new markets addresses unmet needs. It solidifies Qureight's standing. The platform provides enterprise-grade imaging and precision endpoints for clinical trials.
The company's technology offers tangible benefits. It features two core products. "Workflow" slashes imaging decision times. Processes that once took weeks now conclude in 48 hours. "AI Lung" models airways and blood vessels. This product precisely shows drug effects on disease progression. Both applications run on a general-purpose foundation model of the chest. This foundational approach allows rapid deployment of disease-specific models. What once took a year now takes mere months.
Qureight’s platform goes beyond basic imaging. It offers comprehensive global imaging CRO services. These improve image handling in trials. They support rapid site onboarding. They also streamline patient inclusion decisions. Proprietary AI Lung image biomarkers are a key component. These quantify structural changes. They track disease progression with precision. The platform also provides data science products. Synthetic control arms enable comparisons to real trial arms. This reduces study costs and duration.
The global lung and heart clinical trials market shows immense potential. Projections indicate a value of $27.5 billion by 2030. This represents a robust compound annual growth rate (CAGR) of 6.9%. Qureight positions itself strategically within this expanding market. Its end-to-end integrated imaging platform addresses a critical demand. It accelerates clinical trials.
Co-founder Dr. Muhunthan Thillai's personal experience fueled Qureight's inception. As a chest physician, he encountered difficulties interpreting complex CT scans. This experience highlighted a market gap. Pharmaceutical companies needed better tools for clinical trials. Qureight emerged to fill this void in 2018. The company quickly assembled a top-tier team. It hired a CTO from Hewlett Packard. A CMO from CMR Surgical joined. A CSO specializing in machine learning from Imperial College London completed the leadership. This expertise bridged early engineering gaps.
Qureight currently collaborates with major biopharma partners. AstraZeneca and Bristol Myers Squibb are among them. Various biotech partners also utilize its services. These partnerships provide real-time insights. They deliver precision endpoints for accelerated clinical trials. The company's models enhance efficiency. They improve the design of trials.
The decision to partner with Molten Ventures was deliberate. Molten had initially passed on Qureight two years prior. This time, Qureight received multiple term sheets from lead investors. They could have raised even more capital. However, Qureight chose Molten. The relationship proved crucial. It kept the funding round anchored to a London fund. This decision prioritized strategic alignment over competing US offers. Molten Ventures boasts a strong healthtech portfolio. Their investments include Deciphex and CoachHub.
Qureight envisions significant expansion. The company plans to double its headcount to 100 by December. A second London office opens next month. New trials in asthma, lung cancer, and pulmonary hypertension will launch before year-end. This aggressive growth strategy underscores Qureight's ambition. It aims to become the default imaging layer for pharma trials.
The company distinguishes itself from competitors. Oxford's Brainomix is a European peer. Brainomix offers an FDA-cleared e-Lung platform. It focuses on diagnostic software for hospitals. Qureight's focus differs. It provides trial design and imaging contract research services. This distinction creates a clear market segment for Qureight. Its platform was recently selected by Boehringer Ingelheim for a Phase 3 trial.
This $20 million investment marks a pivotal moment. It validates Qureight's innovative approach. It reinforces its leadership in AI-driven medical imaging. The capital ensures Qureight continues to push boundaries. It drives the next generation of medical innovation. The future of clinical trials will rely on such advanced technologies. Qureight is at the forefront of this transformation. Its AI platform promises faster, more accurate drug development. This ultimately benefits patients globally.